18/10/2025
📢 New Publication! 🧠👁️
I’m pleased to share our latest open-access review article, now published in the International Journal of Retina and Vitreous:
🔹 Title: Efdamrofusp alfa: an insight into the novel drug and its use in age-related macular degeneration
👁️ Abstract:
Age-related macular degeneration (AMD) remains one of the leading causes of irreversible blindness among older adults worldwide. This review explores Efdamrofusp alfa (IBI302) — a bispecific decoy receptor fusion protein that targets both VEGF and complement pathways, offering a dual mechanism against neovascular AMD.
Our analysis of preclinical and clinical evidence (66 animal and 880 human subjects) shows that Efdamrofusp alfa effectively reduces retinal thickness, improves visual acuity, and maintains a safety profile similar to current anti-VEGF agents. The findings highlight its potential to become a next-generation therapy for patients unresponsive to monotherapies.
🔬 Conclusion:
Efdamrofusp alfa introduces a promising direction for personalized treatment in neovascular AMD, combining efficacy and safety through dual-pathway inhibition. Further large-scale trials are warranted to confirm its clinical potential.
📖 Read the full article (Open Access): https://pmc.ncbi.nlm.nih.gov/articles/PMC12481782/